Development of a Clinical and Biological Database in Peritoneal Carcinosis (BCB CARCINOSE)

NCT04221464 | Recruiting

• 1 other identifier: PROICM 2019-01 BCA
• Study Type: interventional
• Target: 600
• Locations: 1 country
• Sites: 1

Brief Summary

The creation of a prospective clinical-biological base dedicated to peritoneal carcinosis must therefore be able to serve as a support for this essential search for transfer.

Conditions

Cancer; Peritoneal Carcinosis

Outcome Measures

Primary Outcomes (1)

• Proportion of patients who gave their consent to participate in the study

  The proportion of patients who consent to participate in the study among the screened patients

  Until the study completion: 4 years

Study Arms (1)

Tumors and blood collection

EXPERIMENTAL

For all the patients include in the study : * Blood samples will be collected at different times : before any treatment, at every surgery, one month after any surgery, at progression. * Tumours and not tumours tissues will be collected at different times : Before any surgery, one month after any surgery In parallel to this biological collection, standardized clinical data will be entered into a database treatment, at every surgery

Biological: biological collection; Other: Tissues collections

Interventions

biological collection BIOLOGICAL

Blood samples collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression

Tumors and blood collection

Tissues collections OTHER

Tumours and not tumours tissues will be collected before any treatment (if chemotherapy for example), at every surgery, one month after surgery, at progression

Tumors and blood collection

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient over the age of 18;
• Patient managed for peritoneal carcinosis : digestives origins (pancreatic, gastroesophageal junction, colorectal, bowel) or peritoneum cancer
• Patient eligible for a peritoneal carcinosis treatment : at least one (or more) surgery (s) ;chemotherapy or any treatment for this disease
• Patient agree will all study procedure : biological samples \& tissues samples
• Patient giving informed consent

You may not qualify if:

• Patient not affiliated to Social Protection system
• Patient unable to understand or comply with study instructions or requirements for psychological, family, social or geographical reasons
• The level of French is insufficient to consent to the study and to response to the questionnaires
• Patient under guardianship
• Pregnancy ou breast-feeding women
• Patient treated in case of an emergency

Sponsors & Collaborators

• Institut du Cancer de Montpellier - Val d'Aurelle: lead

Study Sites (1)

Institut du cancer de Montpellier ICM

Montpellier, 34298, France

RECRUITING

MeSH Terms

Conditions

Neoplasms

Study Officials

• François QUENET,MD

  Institut régional du cancer de Montpellier

  STUDY CHAIR

Central Study Contacts

Aurore MOUSSION

CONTACT

467613100; aurore.moussion@icm.unicancer.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 7, 2020
• First Posted: January 9, 2020
• Study Start: November 25, 2019
• Primary Completion (Estimated): February 1, 2028
• Study Completion (Estimated): February 1, 2038
• Last Updated: February 12, 2025

Record last verified: 2025-02

Locations

FR (1)